BioSpace News Archive

Promotion Recognizes Contributions to FINN, Practice Leadership and Continued Client Success and Growth

Don aims to improve his times in four events, while able to do so because of new medications that keep his cancer in check

ANI Pharmaceuticals, Inc. announced that the Company plans to release its fourth quarter and year-to-date 2018 financial results on Wednesday, February 27, 2019, before the opening of the U.S. financial markets.

The Mesothelioma Compensation Center says, “We are appealing to a current or former nuclear power plant worker who has recently been diagnosed with mesothelioma or asbestos exposure lung cancer to call us anytime at 800-714-0303 for direct access to famed mesothelioma attorney Erik Karst founding partner of Karst von Oiste.

Purdue Pharma L.P. today announced the publication of a survey study that found one-third of patients disposed of their unused opioid medication, and those who received education about the importance of safe disposal were approximately three times more likely to do so.

Ra Medical Systems, Inc. (NYSE: RMED), today announced a 98% success rate in the results from a 52-patient study using the company’s groundbreaking DABRA System for the treatment of above- and below-the-knee peripheral artery disease (PAD) in a presentation titled, “Acute Results of a 52-Patient Cohort at a Single Center with the DABRA Atherectomy System,” by Ashok Kondur, MD, FACC, FSCAI.

Urgent First Aid™ reminds businesses that blood can be a risk and a liability for employers in any and every field.

Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced several key appointments to its management team.

Global Technology Company Apptio Modernizes and Simplifies their Employee Healthcare and Benefits Experience by Bringing Accolade Connect to its Employees and their Family Members

ARS Pharmaceuticals announced that ARS-1, an intranasal epinephrine spray in development to treat severe allergic reactions, was granted Fast Track designation by the U.S. Food and Drug Administration